Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Founded in 1998 and headquartered in Søborg, Denmark, it foc... Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Founded in 1998 and headquartered in Søborg, Denmark, it focuses on addressing unmet medical needs in obesity, rare diseases, and chronic inflammation through its validated peptide platform. This expertise has produced over 10 drug candidates advancing to clinical development, with two reaching the market via partnerships. Key products include Zegalogue, a single-use syringe or autoinjector for severe hypoglycemia treatment, and dasiglucagon for congenital hyperinsulinism and bi-hormone artificial pancreas systems. The pipeline features obesity assets like petrelintide (long-acting amylin analog), dapiglutide (GLP-1/GLP-2 dual agonist), and survodutide in Phase 3; rare disease candidates for short bowel syndrome; and inflammation programs such as ZP9830 (Kv1.3 blocker). With around 355 employees, predominantly in R&D, Zealand pursues global partnerships to commercialize therapies, leveraging 25+ years of peptide innovation to enhance biological activity and stability for better patient outcomes.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for Zealand Pharma

We have not yet reviewed Zealand Pharma's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Zealand Pharma's data?

Start your 30-day free trial to request a data review for Zealand Pharma.

Start Free Trial

Legal Center Contact Us